Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success

Benjamin Greenberg, Donna Graves, Gina Remington, Paula Hardeman, Martha Mann, Nitin Karandikar, Olaf Stuve, Nancy L Monson, Elliot Frohman

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis. Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking. Objectives: The objective of this study was to define a rituximab dosing strategy for NMO patients that achieves the lowest rate of relapses. Methods: This was a retrospective chart review of patients treated with various doses of rituximab. Results: Combining data from the NMO and multiple sclerosis (MS) patients, identified that the mean number of days after a 100 mg dose of rituximab until the CD19 population was greater than 2% was 99 days (standard deviation 36, range 43-172). When allowed to rise, the mean number of days after a 1000 mg dose of rituximab until the CD19 population was greater than 2% was 184 (standard deviation 72, range 52-288). The median number of days until a CD19 percentage of 2% was achieved was 133 days in the 100 mg dosing arm and 259 days in the 1000 mg dosing arm. Analysis of the survival curves via both the Mantel-Cox log-rank test and the Wilcoxon test determined that the difference between medial survival for 100 and 1000 mg doses was statistically significant with p-values <0.0001. Conclusions: Low doses of rituximab have a high rate of early B-cell repopulation. Any NMO patient treated with rituximab should be followed with monthly CD19 counts in order to identify the rare, but clinically significant, early repopulators.

Original languageEnglish (US)
Pages (from-to)1022-1026
Number of pages5
JournalMultiple Sclerosis
Volume18
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Neuromyelitis Optica
Therapeutics
Transverse Myelitis
Optic Neuritis
Survival Analysis
Nonparametric Statistics
Rituximab
Population
Multiple Sclerosis
Patient Care
B-Lymphocytes
Guidelines
Recurrence
Survival

Keywords

  • CD19
  • CD20
  • Devic's disease
  • dosing
  • neuromyelitis optica
  • rituximab

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rituximab dosing and monitoring strategies in neuromyelitis optica patients : Creating strategies for therapeutic success. / Greenberg, Benjamin; Graves, Donna; Remington, Gina; Hardeman, Paula; Mann, Martha; Karandikar, Nitin; Stuve, Olaf; Monson, Nancy L; Frohman, Elliot.

In: Multiple Sclerosis, Vol. 18, No. 7, 07.2012, p. 1022-1026.

Research output: Contribution to journalArticle

@article{65645d9c9eb141e3abe9269ba6b7c503,
title = "Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success",
abstract = "Background: Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis. Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking. Objectives: The objective of this study was to define a rituximab dosing strategy for NMO patients that achieves the lowest rate of relapses. Methods: This was a retrospective chart review of patients treated with various doses of rituximab. Results: Combining data from the NMO and multiple sclerosis (MS) patients, identified that the mean number of days after a 100 mg dose of rituximab until the CD19 population was greater than 2{\%} was 99 days (standard deviation 36, range 43-172). When allowed to rise, the mean number of days after a 1000 mg dose of rituximab until the CD19 population was greater than 2{\%} was 184 (standard deviation 72, range 52-288). The median number of days until a CD19 percentage of 2{\%} was achieved was 133 days in the 100 mg dosing arm and 259 days in the 1000 mg dosing arm. Analysis of the survival curves via both the Mantel-Cox log-rank test and the Wilcoxon test determined that the difference between medial survival for 100 and 1000 mg doses was statistically significant with p-values <0.0001. Conclusions: Low doses of rituximab have a high rate of early B-cell repopulation. Any NMO patient treated with rituximab should be followed with monthly CD19 counts in order to identify the rare, but clinically significant, early repopulators.",
keywords = "CD19, CD20, Devic's disease, dosing, neuromyelitis optica, rituximab",
author = "Benjamin Greenberg and Donna Graves and Gina Remington and Paula Hardeman and Martha Mann and Nitin Karandikar and Olaf Stuve and Monson, {Nancy L} and Elliot Frohman",
year = "2012",
month = "7",
doi = "10.1177/1352458511432896",
language = "English (US)",
volume = "18",
pages = "1022--1026",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Rituximab dosing and monitoring strategies in neuromyelitis optica patients

T2 - Creating strategies for therapeutic success

AU - Greenberg, Benjamin

AU - Graves, Donna

AU - Remington, Gina

AU - Hardeman, Paula

AU - Mann, Martha

AU - Karandikar, Nitin

AU - Stuve, Olaf

AU - Monson, Nancy L

AU - Frohman, Elliot

PY - 2012/7

Y1 - 2012/7

N2 - Background: Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis. Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking. Objectives: The objective of this study was to define a rituximab dosing strategy for NMO patients that achieves the lowest rate of relapses. Methods: This was a retrospective chart review of patients treated with various doses of rituximab. Results: Combining data from the NMO and multiple sclerosis (MS) patients, identified that the mean number of days after a 100 mg dose of rituximab until the CD19 population was greater than 2% was 99 days (standard deviation 36, range 43-172). When allowed to rise, the mean number of days after a 1000 mg dose of rituximab until the CD19 population was greater than 2% was 184 (standard deviation 72, range 52-288). The median number of days until a CD19 percentage of 2% was achieved was 133 days in the 100 mg dosing arm and 259 days in the 1000 mg dosing arm. Analysis of the survival curves via both the Mantel-Cox log-rank test and the Wilcoxon test determined that the difference between medial survival for 100 and 1000 mg doses was statistically significant with p-values <0.0001. Conclusions: Low doses of rituximab have a high rate of early B-cell repopulation. Any NMO patient treated with rituximab should be followed with monthly CD19 counts in order to identify the rare, but clinically significant, early repopulators.

AB - Background: Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis. Rituximab therapy has dramatically improved patient care, but standardized dosing regimens and guidelines are lacking. Objectives: The objective of this study was to define a rituximab dosing strategy for NMO patients that achieves the lowest rate of relapses. Methods: This was a retrospective chart review of patients treated with various doses of rituximab. Results: Combining data from the NMO and multiple sclerosis (MS) patients, identified that the mean number of days after a 100 mg dose of rituximab until the CD19 population was greater than 2% was 99 days (standard deviation 36, range 43-172). When allowed to rise, the mean number of days after a 1000 mg dose of rituximab until the CD19 population was greater than 2% was 184 (standard deviation 72, range 52-288). The median number of days until a CD19 percentage of 2% was achieved was 133 days in the 100 mg dosing arm and 259 days in the 1000 mg dosing arm. Analysis of the survival curves via both the Mantel-Cox log-rank test and the Wilcoxon test determined that the difference between medial survival for 100 and 1000 mg doses was statistically significant with p-values <0.0001. Conclusions: Low doses of rituximab have a high rate of early B-cell repopulation. Any NMO patient treated with rituximab should be followed with monthly CD19 counts in order to identify the rare, but clinically significant, early repopulators.

KW - CD19

KW - CD20

KW - Devic's disease

KW - dosing

KW - neuromyelitis optica

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84863195831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863195831&partnerID=8YFLogxK

U2 - 10.1177/1352458511432896

DO - 10.1177/1352458511432896

M3 - Article

C2 - 22261118

AN - SCOPUS:84863195831

VL - 18

SP - 1022

EP - 1026

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 7

ER -